Will Neuralink’s valuation hit __ by December 31?
$65.8K Vol.Closes Jan 1, 2027
↑$60B$7.9K Vol.60%
↑$50B$5.5K Vol.60%
↓$35B$8.2K Vol.56%
↓$32.5B$6.1K Vol.41%
↑$75B$6.8K Vol.21%
↑$100B$27.2K Vol.18%
↓$25B$1K Vol.14%
Elon Musk’s brain-computer interface company, Neuralink, is currently a private firm whose valuation is tracked via Nasdaq Private Market (NPM) data.
The company is founded by Elon Musk and backed by major investors including Sequoia Capital, ARK Invest, and Founders Fund.
Neuralink completed a $650 million Series E round in mid-2025 at a $9 billion valuation, and its share price has surged significantly by mid-2026.
Reaching a $60 billion valuation would signal massive investor confidence in Neuralink’s BCI technology and potential for future IPO or commercial dominance.
Note: NPM valuation data is only published on trading days and updated daily at 1:00 PM ET the following calendar day, which may cause short lag in reflecting real-time valuation shifts.
Neuralink closed a $650 million Series E funding round at a $9 billion pre-money valuation, led by ARK Invest and Sequoia Capital, setting the baseline for subsequent growth.
tsginvest.comNasdaq Private Market estimates Neuralink's price per share at $244.44, reflecting a 586.56% increase from prior levels.
nasdaqprivatemarket.comCurrent private market data indicates a valuation of approximately $14.9B, though some implied market metrics suggest higher valuations up to $46.47B.
premieralts.compolymarket.comAI-generated briefing. AI can make mistakes. This is not financial advice.
Neuralink’s share price per Nasdaq Private Market rose to $244.44 by July 2026, a 586% increase, suggesting rapid valuation expansion toward $60B.
nasdaqprivatemarket.comMarket-implied valuations have reached up to $46.47B as of late July 2026, indicating strong momentum that could push the company past $60B before year-end.
polymarket.comThe company demonstrated real-time cursor control with its first human BCI implant, validating its core technology and increasing investor appetite.
upmarket.coAI-generated briefing. AI can make mistakes. This is not financial advice.
As of late 2025, the official Series E valuation was $9B, and even with growth, reaching $60B requires a nearly 6.7x increase in under two years, which is historically rare for private biotech firms.
tsginvest.comRecent public reports from late 2025 described Neuralink’s valuation at only $5B to $7B, raising concerns about the consistency of higher 2026 estimates.
Yahoo NewsNeuralink has not announced IPO plans or filed SEC documents, limiting liquidity and potentially capping valuation growth compared to public competitors.
stockanalysis.comAI-generated briefing. AI can make mistakes. This is not financial advice.